Brief: Candel Therapeutics Q3 Net Income USD -10.646 Million
14/11/2024 13:00
Nov 14 (Reuters) - Candel Therapeutics Q3 operating expenses USD 8.757 million. * Q3 basic EPS USD -0.33 * Q3 income from operations USD -8.757 million
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Candel Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Candel Therapeutics Reports Second Quarter 2026 Financial Results And Recent Corporate Highlights
Candel Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)